Our Firm | Press | Investor Relations | Events | Contact Us | עברית

Notwithstanding the impressive progress of the Company and its market positioning, the lack of approved treatments in the market and the numerous questions and concerns about the activity make pricing of Pluristem very difficult, similar to the other companies in the field. Accordingly, considering only the CLI indication, we have set a target price of $4.2 per share, with the recommendation of Buy.


Analyst Sabina Podval: The Copaxone patents win is excellent news

Latest offerings

Public Bonds Offering

650 Million NIS

December 2019

See all >


Disclaimer  |  All rights reserved to Leadercm